Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?

Abstract

Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients.
Study Design: Quasi-experimental study.
Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military
Hospital (CMH), Peshawar, Pakistan from August 2022 to 28 February 2023.
Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD
patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low
protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease
treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low
protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and
compared for both groups. SPSS version 23.00 was used for data analysis. The P value ≤ 0.05 was considered
significant.
Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females
were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of
CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A
(low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was
1.48±0.41 mL/ min/ 1.73m2 (P-value<0.000).
Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis
dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis
dependent but still controversial.

How to cite this: Saeed B, Khayam, Afridi Z, Ullah MS. Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?. Life and Science. 2023; 4(4): 427-431. doi: http://doi.org/10.37185/LnS.1.1.407